Pediatric Psoriasis

In this Healio exclusive video, Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, discusses areas of unmet need in the field of psoriasis.

In this Healio exclusive video, Lawrence F. Eichenfield, MD, talks about takeaways in updates on topical treatments for pediatric and adolescent psoriasis discussed at Maui Derm 2025.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the oral molecule apremilast from the Maui Derm 2024 meeting, examining the SPROUT study into apremilast’s use treating psoriasis.

Pediatric patients with psoriasis experienced significant improvement with oral apremilast treatment, according to phase 3 trial results.

In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more.

The FDA has approved a supplemental new drug application for Zoryve expanding its indication to include treatment of psoriasis in pediatric patients, Arcutis Biotherapeutics announced in a press release.

Systemic medications for the treatment of pediatric psoriasis failed to increase serious infection risk, according to a study.

Healio spoke with Joy Wan, MD, MSCE, pediatric dermatologist at Johns Hopkins University, about challenges in pediatric psoriasis, collaborative care and available treatment options.

Pediatric patients with moderate to severe psoriasis experienced encouraging efficacy and safety outcomes through 108 weeks of treatment with ixekizumab, according to a study.